MAPT and Alzheimer disease: Subsequently, in Parkinson's disease models [14] burdened with α‐synuclein and in Alzheimer's disease models [15] laden with Aβ and hyper‐phosphorylated tau, mLVs were found to be structurally compromised and functionally impaired; restoring their integrity markedly reduced pathological protein loads and ameliorated disease phenotypes.